Kura Oncology Reports Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Kura Oncology, Inc. -3.52%

Kura Oncology, Inc.




Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported preliminary clinical data from the first 20 patients in KOMET-007, a Phase 1 dose-escalation trial of the Company's potent and selective menin inhibitor, ziftomenib, in combination with standards of care, including cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza), in patients with NPM1-mutant (NPM1-m) and KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML).

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via